2. Signaling Pathways
  3. Epigenetics
    Metabolic Enzyme/Protease
  4. Methionine Adenosyltransferase (MAT)
  5. Methionine Adenosyltransferase (MAT) Inhibitor

Methionine Adenosyltransferase (MAT) Inhibitor

Methionine Adenosyltransferase (MAT) Inhibitors (13):

Cat. No. Product Name Effect Purity
  • HY-108331
    3-TYP
    		Inhibitor 99.90%
    3-TYP is an inhibitor of SIRT3 (IC50: ~377 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases.
  • HY-112130
    AGI-24512
    		Inhibitor 99.59%
    AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC50 of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer.
  • HY-162135
    MAT2A-IN-14
    		Inhibitor
    MAT2A-IN-14 (compound H3) is a MAT2A inhibitor, and generates reactive oxygen species after sonication to specifically degrade cellular MAT2A via rapid oxidative reactions. Combination of MAT2A-IN-14 and sonication induces 87% MAT2A depletion in human colon cancer cell.
  • HY-162010
    MAT2A-IN-13
    		Inhibitor
    MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research.
  • HY-162353
    AZ'9567
    		Inhibitor
    AZ9567 is a potent MAT2A inhibitor. AZ9567 exhibits antiproliferative activity against MTAP KO HCT116 cells with a pIC50 of 8.9.
  • HY-144184
    MAT2A-IN-6
    		Inhibitor
    MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18).
  • HY-144185
    MAT2A-IN-7
    		Inhibitor
    MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24).
  • HY-144181
    MAT2A-IN-5
    		Inhibitor
    MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1).
  • HY-155149
    MAT2A-IN-12
    		Inhibitor
    MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP-/- cell line).
  • HY-155148
    MAT2A-IN-11
    		Inhibitor
    MAT2A Allosteric inhibitor 1 (compound 5) is a MAT2A selective inhibitor of methionine adenosyltransferase (MAT) with an IC50 of 6.8 nM.
  • HY-161298
    MAT2A-IN-15
    		Inhibitor
    MAT2A-IN-15 (compound 8) is an inhibitor of MAT2A.
  • HY-149915
    MAT2A-IN-10
    		Inhibitor
    MAT2A-IN-10 (Compound 28) is an orally active MAT2A inhibitor with an IC50 of 26 nM. MAT2A-IN-10 can be used for the research of cancer.
  • HY-144179
    MAT2A-IN-4
    		Inhibitor
    MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer.